Home > Back to Publisher > Report Information

Major Pharmaceutical Markets of the Middle East

Urch Publishing
February 14, 2009
89 Pages - SKU: URC2109730

Abstract Table of Contents Search inside this report Related Reports

Countries covered: Middle East

Massive growth is being forecast for the pharmaceutical and biotechnology markets of Middle Eastern states, driven by moves to liberalise national economies, the introduction of mass health insurance and the determination of the region’s governments to become self-sufficient in pharmaceuticals production.”

Major Pharmaceutical Markets of the Middle East (2nd Edition) is a comprehensive report providing extensive coverage of one of the strongest emerging markets. Through quality analysis and forecasts, this unique report will allow you to identify market trends and growth potential opportunities.

This best-selling report provides the necessary background information for a firm to operate in the region.

Chapter summaries:
Chapter 1: covers the main characteristics of the Middle Eastern market through a Political, Economic, Social and Technological (PEST) analysis, plus insight into the tax environment and Free-Trade Agreements in place or being negotiated.
Chapter 2: reports on the Intellectual Property Rights environment of each of the countries covered.
Chapter 3: provides a overview of the regional pharmaceutical market, and includes data on consumption, production, imports, exports, as well as market forecasts.
The other chapters are in-depth per-country market studies.
Country coverage
Egypt, the largest pharmaceutical market of the region Israel, home to the world's largest generic drug company Jordan, the leading Arab pharmaceutical exporter Lebanon, an almost exclusive import market Saudi Arabia, the largest market of the Gulf The United Arab Emirates, among the highest-priced markets in the region Five key findings

Overall the Middle East’s pharmaceutical market is valued at more than $12bn and is expected to grow at healthy 10-15% annually.

There are more than 450 pharmaceutical manufacturers in the Middle East - With the exception of Egypt, all Middle Eastern countries are high importers of branded drugs. Egypt is over 90% self-sufficient in its medicine needs

Saudi Arabia, as the richest regional market, has embarked on an ambitious hospital building project - Major growth drivers are greater access to generics and innovative new medicines as primary care improves and more people are covered by health insurance.

Countries are increasingly adopting liberal economic policies in the healthcare sector Local manufacturing capabilities are constrained to generics. A high acceptance of Western medicines is present What you can learn from this repor

Which multinationals have invested in the Middle East Who are the leading local pharmaceutical manufacturers and distributors What are the trends in the pharmaceutical market and import and export sizes How Intellectual Property Rights and patents are the most conflictual regional issue Which countries have implemented health insurance and the likely impact on growth What type of demand and supply-side cost controls are in place

Executive Summary
Chapter 1: Characteristics of the Middle Eastern Pharmaceutical Market: A Political, Economic, Social and Technological (PEST) Analysis: Political factors; Economic factors; Social factors; Technological factors; Free trade agreements; Euro-Mediterranean Free Trade Area (EU-MEFTA); US-MEFTA (Middle East Free Trade Agreements); Gulf Cooperation Council (GCC); Taxation; Egypt; Israel; Jordan; Lebanon; Saudi Arabia; United Arab Emirates
Chapter 2: Intellectual Property Rights: Trade-related Aspects of Intellectual Property Rights (TRIPS); Egypt; Israel; Jordan; Lebanon; Saudi Arabia; United Arab Emirates
Chapter 3: Overview of the Middle Eastern Pharmaceutical Market: Healthcare overview; Pharmaceutical consumption; Domestic production; Imports; Market forecast
Chapter 4: Egypt: The healthcare structure; The pharmaceutical market; Market figures; Generics; Drug pricing and reimbursement; Distribution; Cost controls; Public tenders; Patient co-payment; Generic substitution; Leading companies
Chapter 5: Israel: The healthcare structure; The pharmaceutical market; Market figures; Drug pricing and reimbursement; Distribution; Cost controls; Prescribing limitations; Generic substitution; Patient co-payment; Leading companies; Focus/point of interest: Teva
Chapter 6: Jordan: The healthcare structure; Health equipment; The pharmaceutical market; Market figures; Focus/point of interest: medical tourism; Drug pricing and reimbursement; Distribution; Cost controls; Co-payment; Public-sector procurement; Leading companies; Focus/point of interest: Hikma
Chapter 7: Lebanon: The healthcare structure; The pharmaceutical market; Market figures; Drug pricing and reimbursement; Distribution; Cost controls; Public procurement; National Drugs Office; Patient co-payment; Leading companies
Chapter 8: Saudi Arabia: The healthcare structure; Pharmaceutical market; Market figures; Drug pricing and reimbursement; Distribution; Cost controls; Private health insurance provision; 'Dollarisation'; Gulf Cooperation Council bulk buying; Leading companies
Chapter 9: United Arab Emirates: The healthcare structure; Pharmaceutical market; Market figures; Drug pricing and reimbursement; Distribution; Cost controls; Bulk buying; Co-payment; Leading companies; Focus/point of interest: Julphar; Focus/point of interest: Neopharma; Focus/point of interest: MENA
Abbreviations
List of Tables: Table 2.1 Watch List status as at 2008; Table 3.1 Size of the pharmaceutical markets in selected countries of the Middle East; Table 3.2 Largest local pharmaceutical companies; Table 3.3 Leading generics players based on 2007 sales; Table 4.1 Egypt's consumer expenditure on health goods and medical services (LEm); Table 4.2 Egypt's retail sales of OTC healthcare (LEm); Table 5.1 Israel's consumer expenditure on health goods and medical services (NISm); Table 5.2 Israel's retail sales of OTC healthcare (NISm); Table 5.3 Teva's sales and net income; Table 6.1 Jordan's consumer expenditure on health goods and medical services (JDm); Table 6.2 Jordan's retail sales of OTC healthcare (JDm); Table 7.1 Lebanese retail sales of OTC healthcare (LLm); Table 7.2 Lebanese consumer expenditure on health goods and medical services (LLm); Table 8.1 Saudi Arabian consumer expenditure on health goods and medical services (SRm); Table 8.2 Saudi Arabian retail sales of OTC healthcare (SRm); Table 9.1 The UAE's consumer expenditure on health goods and medical services (AEDm); Table 9.2 The UAE's retail sales of OTC healthcare (AEDm); Table 9.3 Julphar sales and profits

More Middle East Country Overviews Reports

Lebanon Pharmaceuticals and Healthcare Report Q2 2012 by Business Monitor International
BMI View: Continued improvement in Lebanon's intellectual property (IP) and pharmaceuticalregulatory environment reinforces BMI's view that the country will begin to attract investment in asimilar ...

Kuwait Pharmaceuticals and Healthcare Report Q2 2012 by Business Monitor International
BMI View: While Kuwait will continue to be of interest to multinational drugmakers – on account oftraditional preference for branded medicines and the population’s wealth ...

Israel Pharmaceuticals and Healthcare Report Q2 2012 by Business Monitor International
BMI View: Following widespread protests in mid-2011, the Israeli government has been undersignificant pressure to spend more on housing, healthcare and education. While it was ...

Qatar Pharmaceuticals and Healthcare Report Q2 2012 by Business Monitor International
BMI View: Following Qatar’s decision to reintroduce controls on medicine prices in late 2011, we expect pharmaceutical price inflation to moderate. Consequently, market growth rates ...

Oman Pharmaceuticals and Healthcare Report Q2 2012 by Business Monitor International
BMI View: Oman’s 2012 budget allocated a greater sum of money to the healthcare sector, in line with BMI’s view that the Arab spring would ...

See all reports like this >>

More Middle East Reports

D&B Country RiskLine Report: Yemen by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...

D&B Country RiskLine Report: The United Arab Emirates by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...

D&B Country RiskLine Report: Syria by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...

D&B Country RiskLine Report: Saudi Arabia by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...

D&B Country RiskLine Report: Qatar by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...

See all reports like this >>

Major Pharmaceutical Markets of the Middle East

Share this report

Other tasks

Research Assistance

Related Markets

Country Overviews Reports

Free Alert Me service